Background: Previous studies have suggested that bile acids (BAs) may participate in the
development and/or progression of metabolic dysfunction-associated steatotic liver disease …

Affecting approximately 25% of the global population, steatotic liver disease (SLD) poses a
significant health concern. SLD ranges from simple steatosis to metabolic dysfunction …

Fatty liver index (FLI) was developed as a simple and accurate marker of hepatic steatosis.
FLI is derived from an algorithm based on body mass index, waist circumference, and levels …

To investigate the effects of organic selenium (L-selenocystine, L-selenomethionine, and L-
selenomethylcysteine) on non-alcoholic fatty liver disease (NAFLD), the NAFLD mice model …

Objective: Changes in bile acids (BAs) are increasingly recognized as potential targets for
non-alcoholic steatohepatitis (NASH). Kaempferol has been proved to be anti-inflammatory …

Background/aims Some studies showed that probiotics could improve the composition and
structure of gut microbiota. Changes in the gut microbiota may alter bile acid (BAs) …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to
liver-related morbidity, cardiovascular disease, and metabolic complications. Lifestyle …

Background Our previous studies showed that curcumin prevented hepatic steatosis in
animal models. Objectives This study aimed to assess the effects of curcumin on hepatic fat …

The gut has been a focal point in the research of digestive system disorders. The internal
microbiota generates metabolites that function as signaling molecules and substrates …

Objectives: Plasma bile acid (BA) has been widely studied as pathophysiological factors in
chronic liver disease. But the changes of plasma BA level in lean metabolic dysfunction …